Ichor Life Sciences Completes Acquisition of Woodland Biosciences, Inc.

October 3, 2021

LaFayette, N.Y. — Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, announces it has formally completed the acquisition of Woodland Biosciences, Inc. The in vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichor’s Pharmacology division.

A preclinical contract research organization, Woodland Biosciences was previously located on the campus of Tufts Veterinary Medicine School. Woodland’s R&D facilities have fully relocated from Tufts University to Ichor’s facilities in LaFayette, New York. Dr. Michael Briggs, the President and CSO of Woodland Biosciences, continues as part of Ichor’s scientific leadership in pharmacology. Dr. Briggs has deep expertise and experience in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others. Ichor Life Sciences’ clients and partners will continue to benefit from Dr. Briggs’ involvement in study designs and insights that can progress their preclinical programs.

“Woodland Biosciences’ capabilities in developing orthotopic and syngeneic models with a focus on liver and pancreatic cancers, along with models in NASH and other metabolic diseases, expands the specialization within our Ichor Pharmacology group,” says Dr. Kelsey Moody, PhD, MBA, Ichor Life Sciences’ CEO. “As we seek to continuously add to our portfolio of services and broaden our expertise, we plan to identify other opportunities for acquisitions in the months ahead.”

With these acquisitions and Ichor’s already deep expertise and capabilities in protein sciences and characterization, the company is well suited to provide a more comprehensive set of offerings from discovery through in vivo pharmacology to clients and partners in an innovative and entrepreneurial setting.